Valuation: SCYNEXIS, Inc.

Market Cap 3.77Cr 3.36Cr 3.11Cr 2.82Cr 5.27Cr 357.5Cr 5.35Cr 37Cr 15Cr 187.3Cr 14Cr 14Cr 590.52Cr P/E 2026 *
-1.3x
P/E 2027 * -1.63x
Enterprise Value 3.77Cr 3.36Cr 3.11Cr 2.82Cr 5.27Cr 357.5Cr 5.35Cr 37Cr 15Cr 187.3Cr 14Cr 14Cr 590.52Cr EV / Sales 2026 *
60.8x
EV / Sales 2027 * 5.64x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-0.66%
1 week+3.13%
Current month-23.38%
1 month-14.94%
3 months+1.47%
6 months-53.62%
Current year-25.19%
1 week 3.66
Extreme 3.66
3.98
1 month 3.54
Extreme 3.535
5.51
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
9.12
3 years 3.53
Extreme 3.53
24.56
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
323.2
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 50 09/09/2026
Chief Tech/Sci/R&D Officer - 14/09/2026
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Free

Director

11,500 0.1156%
09/09/26 Free

Chief Financial Officer

1,00,000 1.0051%
01/04/26 Buy

Chief Executive Officer

2,17,390 0.2736%
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%+3.13%-38.56%-71.41% 3.77Cr
-2.54%+1.31%+54.27%+114.96% 1,13500Cr
-1.42%+3.23%+38.56%+74.44% 64TCr
+0.16%+0.08%+25.29%+95.23% 50TCr
-0.31%+3.09%+44.14%+64.80% 38TCr
-1.34%-0.47%+66.04%+41.00% 36TCr
-0.68%+2.65%+22.98%+50.39% 29TCr
-1.20%+3.04%+2.33%+22.86% 27TCr
-1.79%+1.57%+50.56%+59.08% 24TCr
-0.73%-0.10%+29.02%+99.67% 19TCr
Average -1.05%+2.26%+29.46%+55.10% 40.04TCr
Weighted average by Cap. -1.35%+2.66%+41.02%+79.75%

Financials

2026 *2027 *
Net sales 6L 6L 5L 5L 9L 5.88Cr 9L 61.5L 24.35L 3.08Cr 23.25L 22.75L 9.71Cr 66.77L 59.63L 55.09L 49.92L 93.39L 63Cr 94.94L 6.63Cr 2.62Cr 33Cr 2.51Cr 2.45Cr 104.7Cr
Net income -3.06Cr -2.73Cr -2.52Cr -2.28Cr -4.27Cr -290.01Cr -4.34Cr -30Cr -12Cr -151.95Cr -11Cr -11Cr -479.04Cr -3.24Cr -2.9Cr -2.68Cr -2.42Cr -4.54Cr -307.86Cr -4.61Cr -32Cr -13Cr -161.3Cr -12Cr -12Cr -508.52Cr
Net Debt - -
Projected Income Statement - Annual - SCYNEXIS, Inc.
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
23/26/23 $3.785 -0.66% 54,998
22/26/22 $3.810 +0.66% 39,077
21/26/21 $3.785 -0.39% 70,202
20/26/20 $3.800 +3.83% 54,621
19/26/19 $3.660 -0.27% 76,342
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - SCYNEXIS, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.785USD
Average target price
36.33USD
Spread / Average Target
+859.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SCYNEXIS, Inc.
  1. Stock Market
  2. Stocks
  3. SCYX Stock